Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 10;42(35):4119-4122.
doi: 10.1200/JCO-24-01570. Epub 2024 Oct 2.

Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events

Affiliations
Editorial

Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events

Mohamed I Elsaid et al. J Clin Oncol. .

Abstract

In the article that accompanies this editorial, Sun and colleagues utilized large language models (LLMs) to detect immune-related adverse events (irAEs) from electronic health records and demonstrated that LLMs had higher sensitivity than ICD codes alone (94.7% vs 68.7% respectively) and similar specificity, requiring a fraction of the time compared to manual adjudication. This research represents a significant step in enhancing the efficiency of our efforts to better understand irAEs by leveraging data in the electronic medical records from patients treated with immune checkpoint inhibitors over the last 15 years to better predict these toxicities, with the goal of minimizing or mitigating them entirely.

PubMed Disclaimer

References

    1. Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. Mar 2022;86(3):563–572. doi: 10.1016/j.jaad.2021.03.094 - DOI - PMC - PubMed
    1. Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. doi: 10.3389/fimmu.2023.1167975 - DOI - PMC - PubMed
    1. Zhou N, Velez MA, Owen D, Lisberg AE. Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. J Natl Compr Canc Netw. Sep 2020;18(9):1287–1290. doi: 10.6004/jnccn.2020.7640 - DOI - PubMed
    1. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. Jun 10 2018;36(17):1714–1768. doi: 10.1200/jco.2017.77.6385 - DOI - PMC - PubMed
    1. Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. Feb 2020;47(2):166–175. doi: 10.3899/jrheum.190084 - DOI - PubMed

Publication types

LinkOut - more resources